Skip to main content
Top
Published in: Endocrine 2/2009

01-10-2009 | Original Article

The association of adiposity with parathyroid hormone in healthy older adults

Authors: Arpita Patel Pitroda, Susan S. Harris, Bess Dawson-Hughes

Published in: Endocrine | Issue 2/2009

Login to get access

Abstract

Elevated parathyroid hormone (PTH) is a risk factor for increased morbidity and mortality. PTH levels increase with adiposity in older adults but the basis for this association is unclear. The objective of this study was to examine the association of percent body fat (%Fat) with serum PTH in 307 older men and women and to determine the extent to which it may be explained by vitamin D status, bone turnover, calcium metabolism, and glucose homeostasis. The data are from the baseline visit of a clinical trial of calcium and vitamin D to prevent bone loss. %Fat was measured by dual-energy X-ray absorptiometry and fasting blood and urine samples were collected. Serum PTH levels increased by about 0.4 pmol/l per 10 unit increase in percent body fat (P = 0.003). The variables that we examined, including plasma 25-hydroxyvitamin D and serum osteocalcin, calcium, phosphorus, and insulin explained only a small proportion of this association (18%). Further work is needed to identify the mediators of the higher PTH levels in subjects with greater adiposity. This is important in view of worldwide increases in overweight and obesity and the potential contribution of elevated PTH to morbidity and mortality.
Literature
1.
go back to reference R.N. Foley, Clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease, and cardiac failure. Semin. Dial. 16, 111–117 (2003)CrossRefPubMed R.N. Foley, Clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease, and cardiac failure. Semin. Dial. 16, 111–117 (2003)CrossRefPubMed
2.
go back to reference S.G. Rostand, T.B. Drueke, Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int. 56, 383–392 (1999)CrossRefPubMed S.G. Rostand, T.B. Drueke, Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int. 56, 383–392 (1999)CrossRefPubMed
3.
go back to reference F.N. Saleh, H. Schirmer, J. Sundsfjord, R. Jorde, Parathyroid hormone and left ventricular hypertrophy. Eur. Heart J. 24, 2054–2060 (2003)CrossRefPubMed F.N. Saleh, H. Schirmer, J. Sundsfjord, R. Jorde, Parathyroid hormone and left ventricular hypertrophy. Eur. Heart J. 24, 2054–2060 (2003)CrossRefPubMed
4.
go back to reference E. Kamycheva, J. Sundsfjord, R. Jorde, Serum parathyroid hormone levels predict coronary heart disease: The Tromso Study. Eur. J. Cardiovasc. Prev. Rehab. 11, 69–74 (2004)CrossRef E. Kamycheva, J. Sundsfjord, R. Jorde, Serum parathyroid hormone levels predict coronary heart disease: The Tromso Study. Eur. J. Cardiovasc. Prev. Rehab. 11, 69–74 (2004)CrossRef
5.
go back to reference C.P. Kovesdy, S. Ahmadzadeh, J.E. Anderson, K. Kalantar-Zadeh, Obesity is associated with secondary hyperparathyroidism in men with moderate and severe chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2, 1024–1029 (2007)CrossRefPubMed C.P. Kovesdy, S. Ahmadzadeh, J.E. Anderson, K. Kalantar-Zadeh, Obesity is associated with secondary hyperparathyroidism in men with moderate and severe chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2, 1024–1029 (2007)CrossRefPubMed
6.
go back to reference S.K. Ganesh, A.G. Stack, N.W. Levin, T. Hulbert-Shearon, F.K. Port, Association of elevated serum po(4), ca x po(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J. Am. Soc. Nephrol. 12, 2131–2138 (2001)PubMed S.K. Ganesh, A.G. Stack, N.W. Levin, T. Hulbert-Shearon, F.K. Port, Association of elevated serum po(4), ca x po(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J. Am. Soc. Nephrol. 12, 2131–2138 (2001)PubMed
7.
go back to reference M.M. Avram, N. Mittman, M.M. Myint, P. Fein, Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am. J. Kidney Dis. 38, 1351–1357 (2001)CrossRefPubMed M.M. Avram, N. Mittman, M.M. Myint, P. Fein, Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am. J. Kidney Dis. 38, 1351–1357 (2001)CrossRefPubMed
8.
go back to reference L.A. Stevens, O. Djurdjev, S. Cardew, E.C. Cameron, A. Levin, Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J. Am. Soc. Nephrol. 15, 770–779 (2004)CrossRefPubMed L.A. Stevens, O. Djurdjev, S. Cardew, E.C. Cameron, A. Levin, Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J. Am. Soc. Nephrol. 15, 770–779 (2004)CrossRefPubMed
9.
go back to reference M.B. Snijder, P. Lips, J.C. Seidell, M. Visser, D.J. Deeg, J.M. Dekker, R.M. van Dam, Vitamin D status and parathyroid hormone levels in relation to blood pressure: a population-based study in older men and women. J. Intern. Med. 261, 558–565 (2007)CrossRefPubMed M.B. Snijder, P. Lips, J.C. Seidell, M. Visser, D.J. Deeg, J.M. Dekker, R.M. van Dam, Vitamin D status and parathyroid hormone levels in relation to blood pressure: a population-based study in older men and women. J. Intern. Med. 261, 558–565 (2007)CrossRefPubMed
10.
go back to reference J.P. Reis, D. von Muhlen, D. Kritz-Silverstein, D.L. Wingard, E. Barrett-Connor, Vitamin D, parathyroid hormone levels, and the prevalence of metabolic syndrome in community-dwelling older adults. Diabetes Care. 30, 1549–1555 (2007)CrossRefPubMed J.P. Reis, D. von Muhlen, D. Kritz-Silverstein, D.L. Wingard, E. Barrett-Connor, Vitamin D, parathyroid hormone levels, and the prevalence of metabolic syndrome in community-dwelling older adults. Diabetes Care. 30, 1549–1555 (2007)CrossRefPubMed
11.
go back to reference P.N. Sambrook, J.S. Chen, L.M. March, I.D. Cameron, R.G. Cumming, S.R. Lord, J. Schwarz, M.J. Seibel, Serum parathyroid hormone is associated with increased mortality independent of 25-hydroxy vitamin D status, bone mass, and renal function in the frail and very old: a cohort study. J. Clin. Endocrinol. Metab. 89, 5477–5481 (2004)CrossRefPubMed P.N. Sambrook, J.S. Chen, L.M. March, I.D. Cameron, R.G. Cumming, S.R. Lord, J. Schwarz, M.J. Seibel, Serum parathyroid hormone is associated with increased mortality independent of 25-hydroxy vitamin D status, bone mass, and renal function in the frail and very old: a cohort study. J. Clin. Endocrinol. Metab. 89, 5477–5481 (2004)CrossRefPubMed
12.
go back to reference E.N. Taylor, G.C. Curhan, J.P. Forman, Parathyroid hormone and the risk of incident hypertension. J. Hypertens. 26, 1390–1394 (2008)CrossRefPubMed E.N. Taylor, G.C. Curhan, J.P. Forman, Parathyroid hormone and the risk of incident hypertension. J. Hypertens. 26, 1390–1394 (2008)CrossRefPubMed
13.
go back to reference N.H. Bell, S. Epstein, A. Greene, J. Shary, M.J. Oexmann, S. Shaw, Evidence for alteration of the vitamin D-endocrine system in obese subjects. J. Clin. Invest. 76, 370–373 (1985)CrossRefPubMed N.H. Bell, S. Epstein, A. Greene, J. Shary, M.J. Oexmann, S. Shaw, Evidence for alteration of the vitamin D-endocrine system in obese subjects. J. Clin. Invest. 76, 370–373 (1985)CrossRefPubMed
14.
go back to reference M.J. Bolland, A.B. Grey, R.W. Ames, A.M. Horne, G.D. Gamble, I.R. Reid, Fat mass is an important predictor of parathyroid hormone levels in postmenopausal women. Bone 38, 317–321 (2006)CrossRefPubMed M.J. Bolland, A.B. Grey, R.W. Ames, A.M. Horne, G.D. Gamble, I.R. Reid, Fat mass is an important predictor of parathyroid hormone levels in postmenopausal women. Bone 38, 317–321 (2006)CrossRefPubMed
15.
go back to reference E. Kamycheva, J. Sundsfjord, R. Jorde, Serum parathyroid hormone level is associated with body mass index. The 5th Tromso study. Eur. J. Endocrinol. 151, 167–172 (2004)CrossRefPubMed E. Kamycheva, J. Sundsfjord, R. Jorde, Serum parathyroid hormone level is associated with body mass index. The 5th Tromso study. Eur. J. Endocrinol. 151, 167–172 (2004)CrossRefPubMed
16.
go back to reference M.B. Snijder, R.M. van Dam, M. Visser, D.J. Deeg, J.M. Dekker, L.M. Bouter, J.C. Seidell, P. Lips, Adiposity in relation to vitamin D status and parathyroid hormone levels: a population-based study in older men and women. J. Clin. Endocrinol. Metab. 90, 4119–4123 (2005)CrossRefPubMed M.B. Snijder, R.M. van Dam, M. Visser, D.J. Deeg, J.M. Dekker, L.M. Bouter, J.C. Seidell, P. Lips, Adiposity in relation to vitamin D status and parathyroid hormone levels: a population-based study in older men and women. J. Clin. Endocrinol. Metab. 90, 4119–4123 (2005)CrossRefPubMed
17.
go back to reference Z. Ostrowska, K. Zwirska-Korczala, B. Buntner, M. Pardela, M. Drozdz, Assessment of bone metabolism in obese women. Endocr. Regul. 32, 177–181 (1998)PubMed Z. Ostrowska, K. Zwirska-Korczala, B. Buntner, M. Pardela, M. Drozdz, Assessment of bone metabolism in obese women. Endocr. Regul. 32, 177–181 (1998)PubMed
18.
go back to reference M.F. McCarty, C.A. Thomas, PTH excess may promote weight gain by impeding catecholamine-induced lipolysis-implications for the impact of calcium, vitamin D, and alcohol on body weight. Med. Hypotheses 61, 535–542 (2003)CrossRefPubMed M.F. McCarty, C.A. Thomas, PTH excess may promote weight gain by impeding catecholamine-induced lipolysis-implications for the impact of calcium, vitamin D, and alcohol on body weight. Med. Hypotheses 61, 535–542 (2003)CrossRefPubMed
19.
go back to reference Z. Ni, M. Smogorzewski, S.G. Massry, Effects of parathyroid hormone on cytosolic calcium of rat adipocytes. Endocrinology 135, 1837–1844 (1994)CrossRefPubMed Z. Ni, M. Smogorzewski, S.G. Massry, Effects of parathyroid hormone on cytosolic calcium of rat adipocytes. Endocrinology 135, 1837–1844 (1994)CrossRefPubMed
20.
go back to reference E. Chang, S.S. Donkin, D. Teegarden, Parathyroid hormone modulates insulin-stimulated glucose uptake in differentiated adipocytes. FASEB J. 21, A1111 (2007) E. Chang, S.S. Donkin, D. Teegarden, Parathyroid hormone modulates insulin-stimulated glucose uptake in differentiated adipocytes. FASEB J. 21, A1111 (2007)
21.
go back to reference J. Wortsman, L.Y. Matsuoka, T.C. Chen, Z. Lu, M.F. Holick, Decreased bioavailability of vitamin D in obesity [erratum appears in Am. J. Clin. Nutr. 2003 May;77(5):1342]. Am. J. Clin. Nutr. 72, 690–693 (2000) J. Wortsman, L.Y. Matsuoka, T.C. Chen, Z. Lu, M.F. Holick, Decreased bioavailability of vitamin D in obesity [erratum appears in Am. J. Clin. Nutr. 2003 May;77(5):1342]. Am. J. Clin. Nutr. 72, 690–693 (2000)
22.
go back to reference T. Reinehr, G. de Sousa, U. Alexy, M. Kersting, W. Andler, Vitamin D status and parathyroid hormone in obese children before and after weight loss. Eur. J. Endocrinol. 157, 225–232 (2007)CrossRefPubMed T. Reinehr, G. de Sousa, U. Alexy, M. Kersting, W. Andler, Vitamin D status and parathyroid hormone in obese children before and after weight loss. Eur. J. Endocrinol. 157, 225–232 (2007)CrossRefPubMed
23.
go back to reference T. Andersen, P. McNair, L. Hyldstrup, N. Fogh-Andersen, T.T. Nielsen, A. Astrup, I. Transbol, Secondary hyperparathyroidism of morbid obesity regresses during weight reduction. Metabolism 37, 425–428 (1988)CrossRefPubMed T. Andersen, P. McNair, L. Hyldstrup, N. Fogh-Andersen, T.T. Nielsen, A. Astrup, I. Transbol, Secondary hyperparathyroidism of morbid obesity regresses during weight reduction. Metabolism 37, 425–428 (1988)CrossRefPubMed
24.
go back to reference J. Moreiro, O. Ruiz, G. Perez, R. Salinas, J.R. Urgeles, M. Riesco, M. Garcia-Sanz, Parathyroid hormone and bone marker levels in patients with morbid obesity before and after biliopancreatic diversion. Obes. Surg. 17, 348–354 (2007)CrossRefPubMed J. Moreiro, O. Ruiz, G. Perez, R. Salinas, J.R. Urgeles, M. Riesco, M. Garcia-Sanz, Parathyroid hormone and bone marker levels in patients with morbid obesity before and after biliopancreatic diversion. Obes. Surg. 17, 348–354 (2007)CrossRefPubMed
25.
go back to reference E.F. Papakitsou, A.N. Margioris, K.E. Dretakis, G. Trovas, U. Zoras, G. Lyritis, E.K. Dretakis, K. Stergiopoulos, Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women. Maturitas 47, 185–193 (2004)CrossRefPubMed E.F. Papakitsou, A.N. Margioris, K.E. Dretakis, G. Trovas, U. Zoras, G. Lyritis, E.K. Dretakis, K. Stergiopoulos, Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women. Maturitas 47, 185–193 (2004)CrossRefPubMed
26.
go back to reference A. Rogers, R.A. Hannon, R. Eastell, Biochemical markers as predictors of rates of bone loss after menopause. J. Bone Miner. Res. 15, 1398–1404 (2000)CrossRefPubMed A. Rogers, R.A. Hannon, R. Eastell, Biochemical markers as predictors of rates of bone loss after menopause. J. Bone Miner. Res. 15, 1398–1404 (2000)CrossRefPubMed
27.
go back to reference P. Ravn, G. Cizza, N.H. Bjarnason, D. Thompson, M. Daley, R.D. Wasnich, M. McClung, D. Hosking, A.J. Yates, C. Christiansen, Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women early postmenopausal intervention cohort (EPIC) study group. J. Bone Miner. Res. 14, 1622–1627 (1999)CrossRefPubMed P. Ravn, G. Cizza, N.H. Bjarnason, D. Thompson, M. Daley, R.D. Wasnich, M. McClung, D. Hosking, A.J. Yates, C. Christiansen, Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women early postmenopausal intervention cohort (EPIC) study group. J. Bone Miner. Res. 14, 1622–1627 (1999)CrossRefPubMed
28.
go back to reference T. Andersen, P. McNair, N. Fogh-Andersen, T.T. Nielsen, L. Hyldstrup, I. Transbol, Increased parathyroid hormone as a consequence of changed complex binding of plasma calcium in morbid obesity. Metabolism 35, 147–151 (1986)CrossRefPubMed T. Andersen, P. McNair, N. Fogh-Andersen, T.T. Nielsen, L. Hyldstrup, I. Transbol, Increased parathyroid hormone as a consequence of changed complex binding of plasma calcium in morbid obesity. Metabolism 35, 147–151 (1986)CrossRefPubMed
29.
go back to reference R. Hehrmann, J.P. Nordmeyer, H. Mohr, R.D. Hesch, Human parathyroid hormone: antibody characterization. J. Immunoassay 1, 151–174 (1980)CrossRefPubMed R. Hehrmann, J.P. Nordmeyer, H. Mohr, R.D. Hesch, Human parathyroid hormone: antibody characterization. J. Immunoassay 1, 151–174 (1980)CrossRefPubMed
30.
go back to reference L. Lind, H. Lithell, A. Hvarfner, T. Pollare, S. Ljunghall, On the relationships between mineral metabolism, obesity and fat distribution. Eur. J. Clin. Invest. 23, 307–310 (1993)CrossRefPubMed L. Lind, H. Lithell, A. Hvarfner, T. Pollare, S. Ljunghall, On the relationships between mineral metabolism, obesity and fat distribution. Eur. J. Clin. Invest. 23, 307–310 (1993)CrossRefPubMed
31.
go back to reference S. Nagasaka, T. Murakami, T. Uchikawa, S.E. Ishikawa, T. Saito, Effect of glycemic control on calcium and phosphorus handling and parathyroid hormone level in patients with non-insulin-dependent diabetes mellitus. Endocr. J. 42, 377–383 (1995)CrossRefPubMed S. Nagasaka, T. Murakami, T. Uchikawa, S.E. Ishikawa, T. Saito, Effect of glycemic control on calcium and phosphorus handling and parathyroid hormone level in patients with non-insulin-dependent diabetes mellitus. Endocr. J. 42, 377–383 (1995)CrossRefPubMed
32.
go back to reference O.S. Indridason, C.F. Pieper, L.D. Quarles, Predictors of short-term changes in serum intact parathyroid hormone levels in hemodialysis patients: role of phosphorus, calcium, and gender. J. Clin. Endocrinol. Metab. 83, 3860–3866 (1998)CrossRefPubMed O.S. Indridason, C.F. Pieper, L.D. Quarles, Predictors of short-term changes in serum intact parathyroid hormone levels in hemodialysis patients: role of phosphorus, calcium, and gender. J. Clin. Endocrinol. Metab. 83, 3860–3866 (1998)CrossRefPubMed
33.
go back to reference O.S. Indridason, H. Heath 3rd, S. Khosla, D.A. Yohay, L.D. Quarles, Non-suppressible parathyroid hormone secretion is related to gland size in uremic secondary hyperparathyroidism. Kidney Int. 50, 1663–1671 (1996)CrossRefPubMed O.S. Indridason, H. Heath 3rd, S. Khosla, D.A. Yohay, L.D. Quarles, Non-suppressible parathyroid hormone secretion is related to gland size in uremic secondary hyperparathyroidism. Kidney Int. 50, 1663–1671 (1996)CrossRefPubMed
34.
go back to reference K. Olgaard, E. Lewin, Can hyperparathyroid bone disease be arrested or reversed? Clin. J. Am. Soc. Nephrol. 1, 367–373 (2006)CrossRefPubMed K. Olgaard, E. Lewin, Can hyperparathyroid bone disease be arrested or reversed? Clin. J. Am. Soc. Nephrol. 1, 367–373 (2006)CrossRefPubMed
35.
go back to reference B. Dawson-Hughes, S.S. Harris, E.A. Krall, G.E. Dallal, Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N. Engl. J. Med. 337, 670–676 (1997)CrossRefPubMed B. Dawson-Hughes, S.S. Harris, E.A. Krall, G.E. Dallal, Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N. Engl. J. Med. 337, 670–676 (1997)CrossRefPubMed
36.
go back to reference T.C. Chen, A.K. Turner, M.F. Holick, Methods for the determination of the circulating concentration of 25-hydroxyvitamin D. J. Nutr. Biochem. 1, 315–319 (1990)CrossRefPubMed T.C. Chen, A.K. Turner, M.F. Holick, Methods for the determination of the circulating concentration of 25-hydroxyvitamin D. J. Nutr. Biochem. 1, 315–319 (1990)CrossRefPubMed
37.
go back to reference D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985)CrossRefPubMed D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985)CrossRefPubMed
38.
go back to reference J. White, S.S. Harris, G. Dallal, B. Dawson-Hughes, Precision of single versus bilateral hip bone mineral density scans. J. Bone Miner. Res. 17(Supp 1), S314 (2002) J. White, S.S. Harris, G. Dallal, B. Dawson-Hughes, Precision of single versus bilateral hip bone mineral density scans. J. Bone Miner. Res. 17(Supp 1), S314 (2002)
39.
go back to reference E.A. Krall, N. Sahyoun, S. Tannenbaum, G.E. Dallal, B. Dawson-Hughes, Effect of vitamin D intake on seasonal variations in parathyroid hormone secretion in postmenopausal women. N. Engl. J. Med. 321, 1777–1783 (1989)CrossRefPubMed E.A. Krall, N. Sahyoun, S. Tannenbaum, G.E. Dallal, B. Dawson-Hughes, Effect of vitamin D intake on seasonal variations in parathyroid hormone secretion in postmenopausal women. N. Engl. J. Med. 321, 1777–1783 (1989)CrossRefPubMed
Metadata
Title
The association of adiposity with parathyroid hormone in healthy older adults
Authors
Arpita Patel Pitroda
Susan S. Harris
Bess Dawson-Hughes
Publication date
01-10-2009
Publisher
Springer US
Published in
Endocrine / Issue 2/2009
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-009-9231-x

Other articles of this Issue 2/2009

Endocrine 2/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.